John established Badrilla in 2003, combining substantive entrepeneurial experience with a deep understanding of the cardiovascular research field. John received a B.Sc. in Human Biology (Oxford Polytechnic), M.Phil in Medical Biochemistry (University of London) and Ph.D. in Biochemistry (University of Southampton) in the use of monoclonal antibodies as tools to study protein function. After a post-doctoral position at the MRC Cell Regulation Group in Calgary, Canada, he returned to the University of Leeds (1991) as a British Heart Foundation sponsored Lecturer in Cardiac Biochemistry. John’s research speciality is the role of protein phosphorylation in the control of cardiovascular function, and the creation of technologies to observe chemical events in biological specimens. John has maintained an academic research program in basic cardiovascular science and is currently a Professor of Biotechnology at the University of Leeds.
In 1994 he created a life science reagents company, PhosphoProtein Research, which distributed monoclonal and polyclonal antibodies made in the academic laboratory to scientists world-wide. In 1998 John established his second company, Fluorescience Ltd., which developed real-time biosensors for protein phosphorylation, and deployed these in drug discovery. That company was sold to Cyclacel Ltd in 2000.
In addition, John advises academic institutions on translational strategies to deliver impact from their research, and has been active in peer-review and management of interdisciplinary science in the UK (technology, discipline hopping, bio-nanotechnology and synthetic biology).
Paul became Chairman of Badrilla in 2004 and brings a wealth of strategic and industry experience to the Company. An accomplished biochemist, he provides consultancy for businesses and academic institutions and has held senior R&D and management positions across several drug and biotechnology organisations over the last 30 years.
Paul gained his B.Sc. and Ph.D. in Biochemistry from the University of Bristol in the area of intermediary metabolism. After a post -doctoral position with Nobel-laureate Edwin Krebs at the University of California, Davis he returned to the University of Bristol as a Lecturer in Biochemistry. Paul joined Smith, Kline & French R&D (subsequently SmithKline Beecham) in 1985 in the Drug Discovery division and from 1994-1997 he was Vice President Molecular Screening Technologies.
Paul then moved to be Senior Vice President Research at Aurora Biosciences Corp. in San Diego, a company developing ultra-high throughput, highly miniaturised, fluorescence-based screening methodology and automation. Moving back to the UK in 2003 Paul took the role of CEO of ProXara Biotechnology Ltd, a cancer drug discovery company spun out of the University of Bristol focussed on plexstrin-homology domains as drug targets. Since 2007 Paul has been a Director of IOTA Pharmaceuticals Ltd, a spin-out company from the Free University in Amsterdam involved in Fragment-based Drug Discovery.
Paul is an experienced scientist, businessman, and entrepreneur. He has had some thirty five years at executive level within the life science research products and services sector and now assists small and medium sized organizations operating internationally with their strategic scientific, technical, and business growth and development requirements.
Paul brings considerable experience of commercial and scientific management encompassing business growth, development, and financing at both strategic and tactical levels; acquisition and integration; and an extensive and widespread knowledge of commercial and business activities, scientific and new product development, intellectual property protection, and licensing.